Published in Mov Disord on February 01, 2005
Visual hallucinations in dementia with Lewy bodies: transcranial magnetic stimulation study. Br J Psychiatry (2011) 1.58
Non-motor features of Parkinson disease. Nat Rev Neurosci (2017) 1.42
Parkinson's disease as a disconnection syndrome. Neuropsychol Rev (2010) 1.17
Visual symptoms in Parkinson's disease. Parkinsons Dis (2011) 1.17
Early Parkinson's disease and non-motor issues. J Neurol (2008) 1.15
Hallucinations in Parkinson disease. Nat Rev Neurol (2009) 1.13
Pareidolias: complex visual illusions in dementia with Lewy bodies. Brain (2012) 1.11
Parkinson's disease dementia: a neural networks perspective. Brain (2015) 1.10
Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. J Neurol (2005) 1.07
The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord (2010) 1.05
Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain (2014) 0.95
Hallucinations, dreaming, and frequent dozing in Parkinson disease: impact of right-hemisphere neural networks. Cogn Behav Neurol (2008) 0.92
Psychiatric issues in cognitive impairment. Mov Disord (2014) 0.91
Structural alteration of the dorsal visual network in DLB patients with visual hallucinations: a cortical thickness MRI study. PLoS One (2014) 0.88
An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother (2011) 0.85
Hallucinations: Etiology and clinical implications. Ind Psychiatry J (2009) 0.85
Right anterior insula: core region of hallucinations in cognitive neurodegenerative diseases. PLoS One (2014) 0.84
Altered functional organization of the motor system related to ankle movements in Parkinson's disease: insights from functional MRI. J Neural Transm (Vienna) (2011) 0.83
Visual hallucinations in the differential diagnosis of parkinsonism. J Neurol Neurosurg Psychiatry (2012) 0.82
Neural correlates of visual hallucinations in dementia with Lewy bodies. Alzheimers Res Ther (2015) 0.81
A case of progressive posterior cortical atrophy (PCA) with vivid hallucination: are some ghost tales vivid hallucinations in normal people? J Neurol Neurosurg Psychiatry (2006) 0.81
Multi-modal hallucinations and cognitive function in Parkinson's disease. Dement Geriatr Cogn Disord (2010) 0.80
White matter integrity and cognition in Parkinson's disease: a cross-sectional study. BMJ Open (2014) 0.80
Temporal metastates are associated with differential patterns of time-resolved connectivity, network topology, and attention. Proc Natl Acad Sci U S A (2016) 0.80
Multimodal MRI of the hippocampus in Parkinson's disease with visual hallucinations. Brain Struct Funct (2014) 0.77
New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. Parkinsons Dis (2011) 0.76
Neuropsychiatric co-morbidities in non-demented Parkinson's disease. Ann Indian Acad Neurol (2015) 0.76
Visual dysfunction in Parkinson's disease. Brain (2016) 0.75
Why psychosis is frequently associated with Parkinson's disease? Neural Regen Res (2013) 0.75
The psychosis spectrum in Parkinson disease. Nat Rev Neurol (2017) 0.75
Event-Related Potentials in Parkinson's Disease Patients with Visual Hallucination. Parkinsons Dis (2016) 0.75
Oculo-Visual Dysfunction in Parkinson's Disease. J Parkinsons Dis (2015) 0.75
Psychosis in parkinsonism: an unorthodox approach. Neuropsychiatr Dis Treat (2017) 0.75
Compensatory shifts in visual perception are associated with hallucinations in Lewy body disorders. Cogn Res Princ Implic (2017) 0.75
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord (2004) 4.83
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Missing pieces in the Parkinson's disease puzzle. Nat Med (2010) 2.90
White matter changes in mild cognitive impairment and AD: A diffusion tensor imaging study. Neurobiol Aging (2005) 2.79
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2007) 2.62
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol (2003) 2.01
Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device. Mov Disord (2009) 2.00
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Levodopa-induced dyskinesias. Mov Disord (2007) 1.94
The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies. Neurology (2008) 1.92
Rating scales for dystonia: a multicenter assessment. Mov Disord (2003) 1.77
Predicting functional gains in a stroke trial. Stroke (2007) 1.76
Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol (2003) 1.74
Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord (2008) 1.71
A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol (2010) 1.70
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord (2011) 1.70
Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord (2013) 1.68
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Hippocampal disconnection contributes to memory dysfunction in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.63
Neuropathic features in fragile X premutation carriers. Am J Med Genet A (2007) 1.56
Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol (2002) 1.55
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Part 1: the history of 19th century neurology and the American Neurological Association. Ann Neurol (2003) 1.54
Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology (2010) 1.53
Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation. Ann Neurol (2005) 1.48
A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol (2005) 1.48
Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. Mov Disord (2013) 1.44
The origins of scientific cinematography and early medical applications. Neurology (2004) 1.39
Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. Mov Disord (2011) 1.31
The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord (2008) 1.27
Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 1.24
Tremor and ataxia in fragile X premutation carriers: blinded videotape study. Ann Neurol (2003) 1.22
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol (2012) 1.20
Dystonia rating scales: critique and recommendations. Mov Disord (2013) 1.17
Contribution of Jules Froment to the study of parkinsonian rigidity. Mov Disord (2007) 1.16
Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord (2012) 1.15
Hallucinations in Parkinson disease. Nat Rev Neurol (2009) 1.13
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord (2006) 1.12
Fibroblast phenotype in male carriers of FMR1 premutation alleles. Hum Mol Genet (2009) 1.11
Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord (2010) 1.10
Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord (2010) 1.09
Atypical cortical connectivity and visuospatial cognitive impairments are related in children with chromosome 22q11.2 deletion syndrome. Behav Brain Funct (2008) 1.09
Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. Mov Disord (2012) 1.07
Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord (2013) 1.07
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol (2004) 1.07
Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurol Sci (2012) 1.06
Longitudinal changes in white matter following ischemic stroke: a three-year follow-up study. Neurobiol Aging (2005) 1.06
Short-term and practice effects of metronome pacing in Parkinson's disease patients with gait freezing while in the 'on' state: randomized single blind evaluation. Parkinsonism Relat Disord (2004) 1.05
Task force report: scales for screening and evaluating tremor: critique and recommendations. Mov Disord (2013) 1.05
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials (2005) 1.02
Movement disorders caused by medical disease. Semin Neurol (2009) 1.02
Determinants of quality of life in children with Gilles de la Tourette syndrome. Mov Disord (2009) 1.01
Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests? Mov Disord (2014) 1.01
Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. Parkinsonism Relat Disord (2013) 0.99
Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord (2009) 0.98
Hallucinations in Parkinson disease in the prelevodopa era. Neurology (2006) 0.98
The past, present, and future of telemedicine for Parkinson's disease. Mov Disord (2014) 0.97
Assuring interrater reliability for the UPDRS motor section: utility of the UPDRS teaching tape. Mov Disord (2004) 0.97
Which dyskinesia scale best detects treatment response? Mov Disord (2013) 0.97
Teaching program for the Unified Dyskinesia Rating Scale. Mov Disord (2009) 0.96
Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain (2014) 0.95
Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol (2004) 0.95
Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol (2003) 0.95
Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. Parkinsonism Relat Disord (2005) 0.94
Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease. Mov Disord (2011) 0.93
Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). Mov Disord (2010) 0.93
The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol (2006) 0.92
A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol (2009) 0.91
Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov Disord (2010) 0.91
Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. Mov Disord (2011) 0.91
Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord (2009) 0.90